REGENXBIO

REGENXBIO research and develops adeno-associated viral gene therapies for treatment of lysosomal storage disorders and ocular diseases.

Business Model:

Revenue: $483.4M

Employees: 201-500

Detailed REGENXBIO Information

Geographic Data

REGENXBIO headquarters map

Address: 9804 Medical Center Drive

City: Rockville

State: MD

Zip: 20850

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$230M

Raised Total:

$244M

Metrics

2,489,206Website Global Rank

7,258Website Monthly Traffic

Twitter Followers

Description

REGENXBIO research and develops adeno-associated viral gene therapies for treatment of lysosomal storage disorders and ocular diseases.

Contact Phone:
+12405528181

Contact Email:

REGENXBIO went public on 9/8/2015 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
9/8/2015

IPO Valuation:
$492M

Ticker Symbol:
RGNX

IPO Price:
$22/share

Amount Raised:
$138M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
3/2017 Post-IPO Equity $87.2M
11/2013 Venture Round 1 $7.9M Eight Roads Ventures
1/2021 Post-IPO Equity $230.3M
8/2018 Post-IPO Equity $201.8M
5/2011 Grant 1 $2.8M National Institutes of Health
5/2015 Series D $0 RTW Investments
Foresite Capital
Perceptive Advisors
Sectoral Asset Management
Venrock
Cormorant Asset Management
QVT Financial
F-Prime Capital
Tourbillon Global Ventures
Vivo Capital
Brookside Capital
Janus Capital Group
Jennison Associates
RTW Investments
Foresite Capital
Perceptive Advisors
Sectoral Asset Management
Venrock
Cormorant Asset Management
QVT Financial
F-Prime Capital
Tourbillon Global Ventures
Vivo Capital
Brookside Capital
Janus Capital Group
Jennison Associates
3/2013 Grant 2 $7.7M EASME - EU Executive Agency for SMEs
Fondazione Telethon
5/2015 Series D $70.5M Vivo Capital
Venrock
Brookside Capital
Jennison Associates LLC
QVT Financial
Sectoral Asset Management
1/2015 Series C 4 $30M Brookside Capital
Venrock
F-Prime Capital
Deepfield
Brookside Capital
Venrock
1/2020 Post-IPO Equity 1 - Frazier Healthcare Partners
Frazier Healthcare Partners
9/2015 IPO $138.6M
10/2013 Equity $7.9M
1/2015 Series C $27.5M Venrock
Brookside Capital
Deerfield Capital Management
1/2020 Post-IPO Equity 1 - Frazier Healthcare Partners
Frazier Healthcare Partners
5/2015 Series D 14 $70.5M RTW Investments LLC
Foresite Capital
Perceptive Advisors
Sectoral Asset Management
Venrock
Cormorant Asset Management
QVT Financial
F-Prime Capital
Tourbillon Global Ventures
Vivo Capital
RTW Investments LLC
Foresite Capital
Perceptive Advisors
Sectoral Asset Management
Venrock
Cormorant Asset Management
QVT Financial
F-Prime Capital
Tourbillon Global Ventures
Vivo Capital
Announced Date Name Price
8/2017 Dimension Therapeutics

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research